| 1542 |
National Cancer Institute |
Html |
en |
Uterine Sarcoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of uterine sarcomas. |
| cancer treatment | 0.326283 |
| cancer spreads | 0.27392 |
| body | 0.30595 |
| PDQ cancer information | 0.340432 |
| clinical trial search | 0.337812 |
| uterus | 0.36876 |
| metastatic uterine sarcoma | 0.28805 |
| clinical trials | 0.632813 |
| cancer information summary | 0.313263 |
| clinical trial | 0.463679 |
| Transvaginal ultrasound exam | 0.270971 |
| patients | 0.291529 |
| Recurrent uterine sarcoma | 0.312941 |
| total abdominal hysterectomy | 0.33979 |
| treatment clinical trial | 0.271689 |
| NCI PDQ cancer | 0.280198 |
| Treatment Option Overview | 0.316082 |
| radiation therapy | 0.397408 |
| Treatment Editorial Board | 0.278942 |
| General information | 0.276617 |
| general cancer information | 0.27165 |
| treatment | 0.476479 |
| uterine sarcoma cells | 0.294562 |
| NCI-supported cancer | 0.289424 |
| cancer cells | 0.449324 |
|
| Cancer Information Service | 0.272134 |
| Uterine Sarcoma Treatment | 0.298886 |
| Option Overview section | 0.306678 |
| Uterine Cancer Home | 0.286123 |
| treatment clinical trials | 0.296817 |
| National Cancer Institute | 0.35406 |
| new treatment | 0.296864 |
| uterine sarcoma | 0.941913 |
| Uterine Sarcoma section | 0.285791 |
| diagnose uterine sarcoma | 0.300059 |
| PDQ summary | 0.281429 |
| uterine sarcoma spreads | 0.28676 |
| cancer clinical trials | 0.348942 |
| stage | 0.302932 |
| Endometrial Cancer Treatment | 0.295433 |
| high-energy sound waves | 0.275392 |
| fallopian tubes | 0.310914 |
| Tissue Sarcoma Treatment | 0.291575 |
| treatment options | 0.275101 |
| cancer information summaries | 0.270428 |
| comprehensive cancer information | 0.27068 |
| cancer | 0.782046 |
| information | 0.353338 |
| standard treatment | 0.299992 |
|
CLICK HERE |
| 1711 |
National Cancer Institute |
Html |
en |
Breast Cancer Risk in American Women |
A fact sheet that provides statistics about a woman’s risk of developing breast cancer and information about breast cancer risk factors. |
| current incidence rates | 0.345094 |
| Physical activity level | 0.337892 |
| woman’s risk | 0.354657 |
| certain genes | 0.34342 |
| breast cancer increases | 0.425903 |
| Certain breast changes | 0.409974 |
| Mammographic breast density | 0.411613 |
| Indian/Alaska Native women | 0.346578 |
| breast biopsies | 0.390019 |
| Breast Cancer Risk | 0.442755 |
| following risk factors | 0.34953 |
| close male blood | 0.336852 |
| slightly increased risk | 0.378351 |
| lifetime risk | 0.357498 |
| fatty tissue | 0.342031 |
| average American woman | 0.385569 |
| fatty tissue increases | 0.340815 |
| menopausal hormone therapy | 0.39484 |
| current incidence | 0.346194 |
| women | 0.441907 |
| United States | 0.390167 |
| atypical hyperplasia | 0.338604 |
| individual woman | 0.344493 |
| percent | 0.39834 |
|
| full-term pregnancy | 0.359972 |
| breast cancers | 0.393892 |
| specific ages | 0.341748 |
| dense breasts | 0.348222 |
| breast ducts | 0.38994 |
| breast tissue | 0.419467 |
| National Cancer Institute | 0.363645 |
| progestin menopausal hormone | 0.339022 |
| higher risk | 0.34662 |
| strongest risk factor | 0.391772 |
| breast cancer screening | 0.434635 |
| recent SEER Cancer | 0.368992 |
| breast cancer | 0.950607 |
| dense breast tissue | 0.413692 |
| annual SEER reports | 0.34791 |
| risk factor levels | 0.353691 |
| current incidence rate | 0.341921 |
| slight changes | 0.340621 |
| family history | 0.345271 |
| breast cancer incidence | 0.450564 |
| risk | 0.535827 |
| specific time periods | 0.377721 |
| 10-year age intervals | 0.347265 |
| breast cancer statistics | 0.446445 |
|
CLICK HERE |
| 1787 |
National Cancer Institute |
Html |
es |
Prurito (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del prurito (picazón de la piel) como complicación del cáncer y su tratamiento. Se consideran los abordajes de manejo y tratamiento del prurito. |
| funcionamiento renal | 0.688505 |
| cabo pruebas | 0.675786 |
| PDQ Prurito | 0.877657 |
| siguientes aspectos | 0.726626 |
| Diabetes mellitus | 0.704562 |
| Physician Data Query | 0.887758 |
| distintos tipos | 0.680313 |
| Tide Free | 0.679893 |
| cuidado personal | 0.819492 |
| lÃquidos suavizantes | 0.680081 |
| All Free Clear | 0.98679 |
|
| suficientes lÃquidos | 0.704436 |
| largo plazo | 0.693554 |
| medicamentos corticoesteroideos | 0.689382 |
| toallitas suavizantes | 0.68595 |
| determinada afección | 0.743233 |
| National Cancer Institute | 0.676484 |
| bastantes lÃquidos ayuda | 0.75946 |
| siguientes riesgos | 0.661829 |
| siguientes pruebas | 0.722274 |
| ropa all free | 0.721127 |
| Instituto Nacional | 0.734946 |
|
CLICK HERE |
| 3449 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de ano (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de ano y sobre las investigaciones dirigidas a prevenir esta enfermedad. |
| preservativos protege | 0.348482 |
| siguientes factores | 0.806347 |
| suficientes estudios | 0.342762 |
| voluntarios sanos | 0.341993 |
| Physician Data Query | 0.494379 |
| fuerte factor | 0.356186 |
| Estados Unidos | 0.640069 |
| suficiente ejercicio | 0.356939 |
| cuello uterino | 0.913633 |
|
| prevención revisa | 0.348763 |
| PDQ Prevención | 0.389253 |
| largo plazo | 0.344404 |
| principal factor | 0.355962 |
| sexo anal | 0.379093 |
| National Cancer Institute | 0.350168 |
| siguientes riesgos | 0.341101 |
| siguientes prácticas | 0.360133 |
| Instituto Nacional | 0.391026 |
|
CLICK HERE |
| 3675 |
National Cancer Institute |
Html |
en |
Data Submission Under the Genomic Data Sharing (GDS) Policy |
Information for intramural, extramural, and non-NIH funded investigators looking to submit study data under the Genomic Data Sharing (GDS) Policy. |
| data instruments | 0.389578 |
| Different submission requirements | 0.358856 |
| Different data types | 0.458311 |
| data | 0.914172 |
| N/A Arrays | 0.352863 |
| Institutional Certification | 0.390929 |
| data use limitations | 0.365334 |
| phenotype data | 0.455331 |
| DNA sequence data | 0.507348 |
| clinical information | 0.351464 |
| N/A .BAM Arrays | 0.717463 |
| common data elements | 0.45555 |
| NCI intramural research | 0.372571 |
| RNAseq data | 0.381683 |
| submission process | 0.341088 |
| SNP array data | 0.440533 |
| Data reuse | 0.406127 |
| genomic data | 0.788599 |
| genomic program administrator | 0.366093 |
| controlled-access genomic data | 0.507551 |
| Raw data | 0.388186 |
| bisulfite sequencing data | 0.488737 |
| data sharing plan | 0.431561 |
| scientific review | 0.378953 |
|
| basis N/A .TXT | 0.57172 |
| GWAS data | 0.384745 |
| data standards | 0.487591 |
| published table | 0.34424 |
| human genomic data | 0.471234 |
| additional research questions | 0.363874 |
| data processing | 0.449487 |
| GDS policy-covered research | 0.360223 |
| human sample data | 0.554048 |
| GDS website | 0.358009 |
| DNA methylation data | 0.435253 |
| NIH data repositories | 0.466908 |
| minimizes potential errors | 0.345345 |
| data generation | 0.367981 |
| Developing Data Sharing | 0.429887 |
| exposure data | 0.441991 |
| well-documented data standards | 0.480779 |
| genomic data—such | 0.394593 |
| data submission | 0.621641 |
| data release | 0.391289 |
| NIH National Center | 0.357378 |
| genomic data submissions | 0.597871 |
| N/A .BAM NGS | 0.52976 |
|
CLICK HERE |
| 3768 |
National Cancer Institute |
Html |
en |
NCI Research Specialist Award (R50) |
Award enables scientists to pursue stable research careers within an existing cancer research program, but not serve as independent investigators. Letter of Intent due: January 2, 2017 Application due: February 2, 2017 |
| Research Specialist Award | 0.988915 |
| core-based scientists | 0.581471 |
| grant applications | 0.550206 |
| stable research career | 0.730099 |
| NCI-funded cancer research | 0.716667 |
| PM local time | 0.654064 |
| Funding Opportunity Announcements | 0.676968 |
| context | 0.428705 |
| FOA | 0.51866 |
| laboratory-based scientists | 0.56909 |
| sufficient autonomy | 0.601601 |
| grants | 0.427207 |
| cancer research program | 0.718023 |
| development | 0.427246 |
|
| data scientists | 0.569495 |
| researchers | 0.4266 |
| biomedical research enterprise. | 0.720253 |
| Intent | 0.437384 |
| R50 | 0.455052 |
| opportunities | 0.427151 |
| exceptional scientists | 0.586489 |
| applicant organization | 0.552188 |
| Principal Investigators | 0.571254 |
| core facility managers | 0.705581 |
| NCI Research Specialist | 0.740871 |
| career continuity | 0.565048 |
| FOAs | 0.534084 |
| independent investigators. | 0.567464 |
|
CLICK HERE |
| 15636 |
National Cancer Institute |
Html |
null |
Step 6: Post-Award Administration |
Information on numerous requirements that must be met in order to to be in compliance with NIH policy after receiving an award. This includes implementing monitoring systems and keeping financial and programmatic records. |
|
|
CLICK HERE |
| 16254 |
National Cancer Institute |
Html |
es |
Genómica del cáncer |
La investigación de fundamentos genéticos del cáncer ha mejorado nuestro entendimiento de la biología del cáncer y ha conducido a nuevos métodos de diagnosticar y tratar la enfermedad. |
| colores vibrantes | 0.499759 |
| programas de investigación | 0.654055 |
| posibles genes | 0.505721 |
| próxima generación | 0.497158 |
| prácticas de participación | 0.488897 |
| cambios genómicos que | 0.533603 |
| NCI al hacerlos | 0.685799 |
| gen braf | 0.523508 |
| cáncer y programas | 0.967985 |
| proteÃnas. el nci | 0.703749 |
| gen her2 | 0.525613 |
| investigadores representaciones | 0.514115 |
| facilidad de acceso | 0.490645 |
| alta calidad | 0.874691 |
| lÃnea germinal y exposiciones | 0.549891 |
|
| el instituto nacional | 0.489007 |
| cuáles tratamientos | 0.520412 |
| pequeño porcentaje | 0.500295 |
| Genoma Humano | 0.547332 |
| pacientes correctos | 0.574878 |
| tratamientos en investigación | 0.520771 |
| genes candidatos | 0.501572 |
| tratamientos correctos | 0.52447 |
| Estudios ClÃnicos del NCI | 0.817174 |
| determinada terapia | 0.501736 |
| rasgos genómicos y el | 0.775836 |
| mutaciones impulsoras | 0.525134 |
| la investigación aplicable | 0.503499 |
| datos estén | 0.521046 |
|
CLICK HERE |
| 16836 |
National Cancer Institute |
Html |
en |
University of North Carolina, Chapel Hill — Carolina Cancer Nanotechnology Training Program |
The focus of the University of North Carolina Cancer Nanotechnology Training Center is presented here. |
| Alexander Kabanov | 0.504382 |
| collaborations | 0.334208 |
| biomedical engineering | 0.49765 |
| cancer nanotechnology research | 0.762962 |
| individual extramural support | 0.644088 |
| complementary fields | 0.473569 |
| drug delivery | 0.482875 |
| expertise | 0.328758 |
| elite group | 0.473009 |
| report results | 0.469953 |
| Ph.D. | 0.331965 |
| Pilot Grants | 0.459961 |
| Accelerating Module training | 0.637776 |
| C-CNTP | 0.352112 |
| faculty mentors | 0.487076 |
| goal | 0.329691 |
| research experiences | 0.503809 |
| individual cancer nanotechnology | 0.744861 |
| basic biomedical research | 0.665888 |
| D. Sc | 0.501381 |
| schools | 0.328831 |
| cancer nanotechnology | 0.954684 |
| major contribution | 0.490808 |
| strong interests | 0.47614 |
| nanoscience | 0.343997 |
|
| trainee | 0.344494 |
| cancer nanotechnology workforce | 0.813128 |
| didactic courses | 0.522601 |
| highly select cohort | 0.659323 |
| flipped classrooms | 0.506784 |
| conjunction | 0.33003 |
| postdoctoral fellows | 0.767698 |
| UNC-Chapel Hill | 0.513496 |
| Principal Investigator | 0.508626 |
| diverse backgrounds | 0.477553 |
| clinical science | 0.481941 |
| co-mentored research experience | 0.637969 |
| capabilities | 0.328356 |
| material sciences | 0.483342 |
| didactic training | 0.542719 |
| oral communications skills | 0.612488 |
| North Carolina CNTC | 0.607228 |
| outstanding Program faculty | 0.670768 |
| team | 0.328965 |
| key areas | 0.46905 |
| outstanding postdoctoral experience | 0.731407 |
| Training Focus | 0.521321 |
| objectives | 0.371588 |
| growth | 0.329544 |
|
CLICK HERE |
| 16861 |
National Cancer Institute |
Html |
es |
Terapia Gerson (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de la terapia Gerson como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| múltiples detalles | 0.301338 |
| Centro Nacional | 0.302469 |
| New Hampshire Avenue | 0.301732 |
| Drug Administration | 0.301078 |
| NCI Best Case | 0.303308 |
| Max B | 0.30156 |
| datos bibliográficos pubmed | 0.30187 |
| cuerpo suficientes vitaminas | 0.303678 |
| Vitaminas A | 0.301419 |
| siguientes preguntas | 0.30102 |
| National Cancer Institute | 0.302137 |
| siguientes riesgos | 0.301292 |
| vitamina b12 | 0.301563 |
| alto contenido | 0.301449 |
| Instituto Nacional | 0.314894 |
| Gerson Research Organization | 0.308778 |
| Salud Complementaria | 0.303978 |
| Visuals Online | 0.301269 |
|
| complementarias revisa | 0.301833 |
| PDQ Terapia Gerson | 0.311186 |
| Physician Data Query | 0.307427 |
| comidas vegetarianas | 0.301548 |
| coenzima q10 | 0.304748 |
| Estados Unidos | 0.316664 |
| enzimas pancreáticas | 0.305305 |
| libre uso | 0.301348 |
| página manejo | 0.301179 |
| ¿El tratamiento | 0.302348 |
| suficiente potasio | 0.301916 |
| ¿Los beneficios | 0.301092 |
| juntos cam | 0.301043 |
| numerosos detalles | 0.301552 |
| Series Program | 0.301073 |
| terapia gerson | 0.988974 |
| medicina complementaria | 0.349955 |
|
CLICK HERE |